NiceR

Beyond imlifidase, we are developing a next generation of enzymes designed to allow repeat dosing administration through our Novel Immunoglobulin Cleaving Enzymes for Repeat Dosing, or NiceR, program.

Due to the immunogenicity observed, we believe imlifidase may not be suitable for chronic diseases that would require several administrations. Under the NiceR program, we are developing IgG-cleaving enzymes designed to have lower propensity to induce immunity. This would allow to increase the therapeutic window, and, more importantly, to use these enzymes in a number of IgG-driven autoimmune diseases where patients experience flares or in transplantation where repeat dosing would be beneficial and add further value, particularly post-transplant. We believe that candidates identified in the NiceR program could be evaluated across a large spectrum of potential indications, including a number of gene therapy and oncology indications.